Publication Name	World Journal of Gastrointestinal Pathophysiology
Manuscript ID	93606
Country	United States

Received	2024-03-01 22:18
Peer-Review Started	2024-03-01 22:18
To Make the First Decision
Return for Revision	2024-04-30 02:53
Revised	2024-05-14 01:54
Second Decision	2024-07-22 02:43
Accepted by Journal Editor-in-Chief
Accepted by Executive Editor-in-Chief	2024-07-23 09:54
Articles in Press	2024-07-23 09:54
Publication Fee Transferred
Edit the Manuscript by Language Editor
Typeset the Manuscript	2024-08-12 00:49
Publish the Manuscript Online	2024-08-22 09:36

ISSN	2150-5330 (online)
Open Access	This article is an open-access article that was selected by an in-house editor and fully peer-reviewed by external reviewers. It is distributed in accordance with the Creative Commons Attribution NonCommercial (CC BY-NC 4.0) license, which permits others to distribute, remix, adapt, build upon this work non-commercially, and license their derivative works on different terms, provided the original work is properly cited and the use is non-commercial. See: https://creativecommons.org/Licenses/by-nc/4.0/
Copyright	The Author(s) 2024. Published by Baishideng Publishing Group Inc. All rights reserved.
Article Reprints	For details, please visit: http://www.wjgnet.com/bpg/gerinfo/247
Permissions	For details, please visit: http://www.wjgnet.com/bpg/gerinfo/207
Publisher	Baishideng Publishing Group Inc, 7041 Koll Center Parkway, Suite 160, Pleasanton, CA 94566, USA
Website	http://www.wjgnet.com

Category	Gastroenterology & Hepatology
Manuscript Type	Review
Article Title	Team players in the pathogenesis of metabolic dysfunctions-associated steatotic liver disease: The basis of development of pharmacotherapy
Manuscript Source	Unsolicited Manuscript
All Author List	Shahid Habib
Funding Agency and Grant Number
Corresponding Author	Shahid Habib, FCPS, MBBS, MRCP, Researcher, Department of Hepatology, Liver Institute PLLC, 2830 N Swan Road, Suite 180, Tucson, AZ 85712, United States. shabib@liverinstitutepllc.org
Key Words	Metabolic dysfunctions-associated steatotic liver disease; Visceral adiposity; Obesity; Farnesoid X receptor; Peroxisome proliferator-activated receptor; Insulin; Adiponectin; Glucagon-like peptide-1; Genetics; PNPLA3; TM6SF2; Diabetes; Dyslipidemia; Pathogenesis
Core Tip	The pathogenesis of metabolic dysfunctions associated steatotic liver disease (MASLD) is complex and a thorough analysis of the contributing factors to disease progression is pivotal to individualized patient care. Understanding and identifying the key pathogenic processes responsible for MASLD in each patient allows for the utilization of appropriate and effective pharmacotherapy. This review details the various key players in MASLD pathogenesis, through the lens of carbohydrate and fat metabolism, to divulge new areas of focus that could strengthen the capability of precision medicine for this population of patients.
Publish Date	2024-08-22 09:36
Citation	<p>Habib S. Team players in the pathogenesis of metabolic dysfunctions-associated steatotic liver disease: The basis of development of pharmacotherapy. <i>World J Gastrointest Pathophysiol</i> 2024; 15(4): 93606</p>
URL	https://www.wjgnet.com/2150-5330/full/v15/i4/93606.htm
DOI	https://dx.doi.org/10.4291/wjgp.v15.i4.93606

Full Article (PDF)	WJGP-15-93606-with-cover.pdf
Manuscript File	93606_Auto_Edited_070120.docx
Answering Reviewers	93606-answering-reviewers.pdf
Audio Core Tip	93606-audio.m4a
Conflict-of-Interest Disclosure Form	93606-conflict-of-interest-statement.pdf
Copyright License Agreement	93606-copyright-assignment.pdf
Supplementary Material	93606-supplementary-material.pdf
Peer-review Report	93606-peer-reviews.pdf
Scientific Misconduct Check	93606-scientific-misconduct-check.png
Scientific Editor Work List	93606-scientific-editor-work-list.pdf
CrossCheck Report	93606-crosscheck-report.pdf